The facility is expected to be operational in 2025. Credit: Glencar Construction.

UK-based Glencar Construction has been appointed to build a new Moderna Innovation and Technology Centre (MITC) at the Harwell Campus in Oxfordshire.

The £150m project will feature a research, development and manufacturing facility.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This facility is expected to offer improved access to mRNA vaccines for several respiratory diseases.

Furthermore, the facility will comprise a clinical biomarker laboratory, which is a prefabricated modular laboratory built in Northumberland and then installed on-site.

Glencar CEO Eddie McGillycuddy said: “Having successfully delivered The Vaccine Manufacturing and Innovation Centre (VMIC) and established a life science office within the Harwell Science and Innovation Campus, we are absolutely delighted to now be delivering this pioneering research and development facility.

See Also:

“We very much look forward to working with the team at Moderna and Merit to develop this important new facility and further expand the thriving health tech cluster at Harwell.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Construction will commence this year with the facility expected to become operational in 2025, subject to approvals from the planning and regulatory authorities.

Harwell Campus chief executive Stuart Grant said: “mRNA technology has the capability to transform how we treat a variety of diseases and enhance UK resilience against future pandemics.

“I’m delighted to welcome Moderna to Harwell Campus, and our thriving health tech cluster.

“We’re entering a new era of medicine so it’s important that we deliver and build cutting-edge facilities to reflect this and spaces that promote innovation and encourage collaboration.”